SecBot SecBot
8-K ·Filed Jul 30, 2026

LH

LABCORP HOLDINGS INC.
BULLISH
Impact 7/10
Horizonweeks Processed3mo ago SEC0000920148-26-000162
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The beat-and-raise quarter with margin expansion and a $1.0B buyback authorization is a strong bullish signal. Traders should watch for continued execution on organic growth (4.2% organic revenue growth) and further margin expansion as the company benefits from operating leverage and its LaunchPad cost initiatives.

DirectionBullish
Confidencehigh
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$315.53
T+0 close · Jul 30, 2026 · via day close
Latest settled
+4.25%
T+60 · $328.95
Vs SPY
+1.79%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 30 $315.53entry
  2. T+1 · 4mo ago −2.01%α −2.71% · $309.20
  3. T+5 · 3mo ago +0.32%α −3.31% · $316.53
  4. T+20 · 3mo ago +6.66%α +2.69% · $336.54
  5. T+60 · 25d ago +4.25%α +1.79% · $328.95
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Labcorp reported Q2 2026 revenue of $3.73B (up 5.8% YoY) and adjusted EPS of $4.99, beating consensus of $4.77 by 4.6%. The company raised full-year 2026 adjusted EPS guidance to $18.10-$18.55 (up $0.30 at midpoint) and increased its share repurchase authorization by $1.0B to $1.4B. Strong operating margin expansion (adjusted operating margin +70bps to 15.8%) and double-digit adjusted EPS growth (+14.9% YoY) drove the beat, with both Diagnostics and Biopharma segments contributing to the upside.

Key Financial Metrics

EPS
$4.99
est $4.77 · +4.6%
Revenue
$3.7B
est $3.7B · +0.6% · +5.8% YoY
Rating
beat
Guidance
$14.71B-$14.827B
raised
Free Cash Flow
$313.9M
Gross Margin
29.8%

Key Facts

  • Q2 2026 revenue $3.73B vs $3.53B YoY, up 5.8%
  • Adjusted EPS $4.99 vs consensus $4.77, a 4.6% beat
  • Raised full-year 2026 adjusted EPS guidance to $18.10-$18.55 (up $0.30 at midpoint)
  • Raised full-year revenue growth guidance to 5.4%-6.3% (up 30bps at midpoint)
  • Adjusted operating margin expanded 70bps to 15.8%
  • Board approved $1.0B increase in share repurchase authorization, bringing total to $1.4B
  • Repurchased $353.8M of stock and paid down $500M in senior notes during Q2
  • Diagnostics segment revenue +5.5% YoY, Biopharma segment revenue +6.5% YoY

Financial Impact

Q2 revenue $3.73B, adjusted EPS $4.99, raised FY guidance midpoint by $0.30 to $18.10-$18.55

revenueadjusted EPSoperating marginshare repurchase authorization

Risk Factors

  • Execution risk on integrating recent acquisitions ($225.7M in Q2)
  • Potential impact from foreign exchange headwinds (0.4% on enterprise revenue guidance)
  • Competitive pressures in the laboratory services market

Market Snapshot

Exchange
NYSE
Sector
Services-Medical Laboratories
Analyst Consensus
82% bullish (28 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000920148-26-000162
Document: lh-20260730.htm0000920148-26-000162
Document: 0000920148-26-000162-index-headers.html0000920148-26-000162
Document: 0000920148-26-000162-index.html0000920148-26-000162
Document: 0000920148-26-000162.txt0000920148-26-000162
8-K Data (Synthetic)0000920148-26-000162

Track record

29 reports on LH

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +17.60% at T+60 after the Apr 30, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $372.32 Now $372.46 +0.04% settles Nov 19
  2. Nov 10, 20266d ago 144 Neutral 2/10 Entry $372.23 Now $372.46 +0.06% settles Nov 18
  3. Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $363.30 to $372.32 Now $372.46 +2.52% ▲ +2.48% −0.81% vs SPY
  4. Nov 4, 202612d ago 144 Neutral 2/10 Entry $367.79 to $372.23 Now $372.46 +1.27% ▲ +1.21% +2.12% vs SPY
  5. Nov 4, 202612d ago 8-K Neutral 2/10 Entry $367.79 to $372.23 Now $372.46 +1.27% ▲ +1.21% +2.12% vs SPY
  6. Nov 3, 202613d ago 144 Neutral 2/10 Entry $353.92 to $370.88 Now $372.46 +5.24% ▲ +4.79% +5.38% vs SPY
  7. Oct 30, 202617d ago 144 Neutral 2/10 Entry $361.39 to $366.57 Now $372.46 +3.06% ▲ +1.43% +4.14% vs SPY
  8. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $360.25 to $367.79 Now $372.46 +3.39% ▲ +2.09% +2.81% vs SPY
  9. Oct 26, 202621d ago Institutional Cluster Neutral 3/10 Entry $329.90 to $361.39 Now $372.46 +12.90% ▲ +9.55% +10.81% vs SPY
  10. Oct 21, 202626d ago 8-K Neutral 2/10 Entry $323.75 to $331.17 Now $372.46 +15.05% ▲ +2.29% +2.74% vs SPY
Showing 10 of 29

US Market Status

Market Closed · Opens in 8h 51m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 30, 2026